Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 6Leukemia, Myeloid, Acute 6Leukemia 4Carcinoma 3Hematologic Diseases 2Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Carboplatin 42Etoposide 37Cisplatin 23Topotecan 22Nivolumab 17pembrolizumab 12atezolizumab 12Ipilimumab 10Paclitaxel 9durvalumab 8Irinotecan 8Radiosurgery 6Pemetrexed 6rovalpituzumab tesirine 5Magnetic Resonance Spectroscopy 5trioctyl phosphine oxide 4trilaciclib 4etoposide phosphate 4berzosertib 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4Dexamethasone 4veliparib 3tremelimumab 3olaparib 3carfilzomib 3cabozantinib 3Temozolomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Small Cell Lung Carcinoma × vosaroxin × Clear all
NCT00298896 2018-07-26

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Sunesis Pharmaceuticals

Phase 2 Completed
55 enrolled 10 charts
Thoracic

Carcinoma, Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡